Androgenic-anabolic steroid drug-induced liver injury

摘要

Bodybuilders and athletes frequently abuse androgenic-anabolic steroids (AAS), which have both physiological and metabolic consequences. The prevalence of AAS abuse is increasing, with reported rates of 15-30% in weight trainers in health clubs and gyms.1 AAS are increasingly being used for their cosmetic benefit, with the number of reported steroid users increasing in the high school population group; approximately 6.6% of year 12 students in America were reported to have taken AAS in 1988. More recent reports estimate rates of 3-12% of male and 0.5-2% of female adolescents.2 Similar figures have been reported in several countries in Europe, and in Australia and Brazil, with a lifetime prevalence of AAS use between 1% and 6% for high school students, and between 9% and 38% among bodybuilders.3 This trend has not only resulted in an increase in anabolic-steroid-associated reproductive and endocrine disorders, myocardial hypertrophy, stroke, aggression, and depression, but has also been associated with hepatocellular injury. Due to the illicit nature of AAS and the relative paucity of reported cases, there is little consensus on diagnosis, monitoring or therapy for AAS-induced hepatocellular injury.